Trial Profile
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Ruxolitinib (Primary) ; Methylprednisolone
- Indications Multiple myeloma; Plasmacytoma
- Focus Adverse reactions
- Acronyms I-RUX
- 21 Dec 2023 According to American Oncology Network media release, data from the study were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
- 30 Oct 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2024.
- 20 Dec 2022 According to an ONCOtherapeutics media release, results from this trial were published online in the British Journal of Haematology